Cargando…
Use of Surrogate end points in HTA
The different actors involved in health system decision-making and regulation have to deal with the question which are valid parameters to assess the health value of health technologies. So called surrogate endpoints represent in the best case preliminary steps in the casual chain leading to the rel...
Autores principales: | Mangiapane, Sandra, Velasco Garrido, Marcial |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
German Medical Science GMS Publishing House
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011277/ https://www.ncbi.nlm.nih.gov/pubmed/21289899 http://dx.doi.org/10.3205/hta000074 |
Ejemplares similares
-
Surrogate end points and their role in clinical trial
por: Jaykaran,
Publicado: (2009) -
Optimizing the implementation of future treatment using surrogate end-points
por: Dowsett, Mitch
Publicado: (2008) -
Debate: Are surrogate end-point studies worth the effort?
por: Valabhji, Jonathan, et al.
Publicado: (2000) -
Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018) -
Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)